Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Journal:

The New England Journal of Medicine

Published:

2026-06-01

DOI:

10.1056/nejmoa2603878

Affiliations:

24

Authors:

23

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	6.000000	0.26
Johnson & Johnson, UK, United Kingdom (UK)	1.000000	0.04
Rio de Janeiro State University (UERJ), Brazil	1.000000	0.04
Vita-Salute San Raffaele University (UniSR), Italy	1.000000	0.04
LabCorp, United States of America (USA)	1.000000	0.04
Harvard Medical School (HMS), United States of America (USA)	1.000000	0.04
Northwestern University (NU), United States of America (USA)	1.000000	0.04
The University of British Columbia (UBC), Canada	1.000000	0.04
Mass General Brigham, United States of America (USA)	1.000000	0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.04
University Hospital of Cologne, Germany	1.000000	0.04
START Carolinas, United States of America (USA)	1.000000	0.04
Oregon Health and Science University (OHSU), United States of America (USA)	1.000000	0.04
Hospital de Jerez de la Frontera, Spain	1.000000	0.04
University of Miyazaki, Japan	1.000000	0.04
Southern Alberta Institute of Urology (SAIU), Canada	0.500000	0.02
University of Nevada, Reno (UNR), United States of America (USA)	0.500000	0.02
University of Calgary (U of C), Canada	0.500000	0.02
Renown Health, United States of America (USA)	0.500000	0.02
German Consortium of Translational Cancer Research (DKTK), Germany	0.333333	0.01
Essen University Hospital, Germany	0.333333	0.01
University of Duisburg-Essen (UDE), Germany	0.333333	0.01